Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Xenon Pharmaceuticals Inc. (XENE : NSDQ)

• Company Description    Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada. Number of Employees: 327

• Price / Volume Information    Yesterday's Closing Price: $31.42 Daily Weekly Monthly 20 Day Moving Average: 1,442,651 shares Shares Outstanding: 76.73 (millions) Market Capitalization: $2,410.97 (millions) Beta: 1.10 52 Week High: $46.00 52 Week Low: $26.74 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.30% -5.23% 12 Week -4.87% -17.54% Year To Date -19.85% -24.27%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3650 GILMORE WAY - BURNABY,A1 V5G 4W8 CAN ph: 604-484-3300 fax: 604-484-3450 investors@xenon-pharma.com http://www.xenon-pharma.com

• General Corporate Information    Officers Ian Mortimer - Chief Executive Officer; President and Director Dawn Svoronos - Chairman Sherry Aulin - Chief Financial Officer Gillian Cannon - Director Steven Gannon - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 98420N105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 76.73 Most Recent Split Date: (:1) Beta: 1.10 Market Capitalization: $2,410.97 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.07 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 12.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 12.57% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.42 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -33.87% vs. Previous Quarter: 1.19% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -32.44 12/31/24 - -28.54 ROA 06/30/25 - - 03/31/25 - -30.84 12/31/24 - -27.27 Current Ratio 06/30/25 - - 03/31/25 - 17.66 12/31/24 - 17.85 Quick Ratio 06/30/25 - - 03/31/25 - 17.66 12/31/24 - 17.85 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -3,406.93 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 9.19 12/31/24 - 9.90 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©